Literature DB >> 25606084

Recurrent stroke: what have we learnt?

K Rabia1, Em Khoo2.   

Abstract

Stroke is the third leading cause of death, a major cause of disability in adults, and is frequently more disabling than fatal. With a decline in mortality from initial cerebral infarction and an increase in the life expectancy of the population, the number of patients with recurrent stroke and ensuing cardiovascular events will become greater. Thus it is important to find out those patients at high risk of stroke recurrence. This case report illustrates the process of recurrent stroke and the resulting disabilities and morbidities in a 42-year- old man. The role of integrated stroke rehabilitation programme is described.

Entities:  

Keywords:  Stroke; prevention; rehabilitation

Year:  2007        PMID: 25606084      PMCID: PMC4170336     

Source DB:  PubMed          Journal:  Malays Fam Physician        ISSN: 1985-2274


  19 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Carotid endarterectomy for symptomatic carotid stenosis.

Authors:  C S Cina; C M Clase; R B Haynes
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Authors:  G J Hankey; C L Sudlow; D W Dunbabin
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

Authors:  H C Diener; L Cunha; C Forbes; J Sivenius; P Smets; A Lowenthal
Journal:  J Neurol Sci       Date:  1996-11       Impact factor: 3.181

5.  Atenolol in hypertension: is it a wise choice?

Authors:  Bo Carlberg; Ola Samuelsson; Lars Hjalmar Lindholm
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 9.  Stroke: strategies for primary prevention.

Authors:  Justin A Ezekowitz; Sharon E Straus; Sumit R Majumdar; Finlay A McAlister
Journal:  Am Fam Physician       Date:  2003-12-15       Impact factor: 3.292

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.